To explore the treatment effect of Weihe granule II on CAG by analyzing the expression level of EGF and EGFR in gastric mucosal of model rats of CAG treated with Weihe granule II. Methods：Seventy-two male Wistar rats were randomly divided into two groups, control group (n=12) and model group (n=60). The rat model of CAG in model group was created using comprehensive modeling method. Then, all rats in model group were assigned into five sub-groups, namely model sub-group, Vitacoenzyme control sub-group, low-dose sub-group, mediate-dose sub-group and high-dose Weihe granule II sub-groups. After all rats in each group were subjected to the corresponding treatments for 60 days, the expression level of EGF and EGFR in the same gastric tissue of each rat were be examined and compared with other groups. Results： The expression of EGF in the high-dose Weihe granule II sub-group (1.25±0.16) was lower than that in model sub-group (2.98±0.15), (P<0.01); the expression of EGFR, in the high-dose Weihe granule II sub-group (1.636±0.809) was lower than that in model sub-group (3.300±1.337) (P<0.01). Conclusion： Weihe granule II can treat CAG by decreasing the expression levels of EGF and EGFR in gastric mucosal to repair the gastric mucosal cells and inhibit the excessive proliferation for cancer prevention.